Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX) has filed a Shelf Registration in the amount of $250 million. Progenics Pharmaceuticals intends to use some of proceeds of in-licensing of technology, establishment of research and development collaborations, and/or merger or acquisition opportunities.